Normunity is a biotechnology company creating novel anti-cancer therapies that address untapped biology at the interface of the immune system and the tumor to target mechanisms that impact tumor growth and circumvent immune surveillance and tumor clearance. The company is using these novel targets to build a pipeline of anti-cancer medicines, including therapeutic antibodies, bispecific antibodies, and payload-carrying biologics. The company's lead program, NRM'823, is a T cell engager with tumor-specific targeting for multiple solid tumors and is expected to enter the clinic in 2025.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 01/13/25 | $75,000,000 | Series B |
Canaan Partners Connecticut Innovations Enavate Sciences  Hong Kong Inno Capital HongShan Capital Group Osage Venture Partners Pfizer Venture Investments Regeneron Ventures Samsara BioCapital Sanofi Ventures Taiho Ventures YK Bioventures | undisclosed |
